When does this change take effect?

This change is effective Nov 17, 2025.

Back to dashboard

CommercialDocumentationMedium impact

08.00.75q, Erythropoiesis-Stimulating Agents (ESAs)

Q: Who is affected by this change?

This affects Independence Blue Cross Nephrology, Oncology, Hematology, Internal Medicine providers on Commercial plans.

Independence Blue Cross·Nephrology, Oncology, Hematology +1 more·Medical Policy

Effective date

Nov 17, 2025

We identified it

Jun 19, 2026

Days to comply

—

Summary

IBX has updated their medical policy for Erythropoiesis-Stimulating Agents (ESAs), affecting medical necessity criteria and medical coding requirements. This change impacts how ESA treatments must be documented and billed for commercial insurance patients.

Action Required

Action needed

By November 17, 2025: Billing team must review updated medical necessity criteria for ESA treatments and update documentation requirements in EMR templates. Providers treating patients with anemia or chronic kidney disease should verify new coding guidelines for ESA administration before submitting claims to IBX commercial plans.

Related policy hubs

Independence Blue Cross policies Nephrology Oncology Hematology Internal Medicine